About Us
We are a privately-held clinical stage biopharmaceutical company backed by a consortium of dedicated family offices. We are ushering in a new era in the treatment of cancers and immune disorders by harnessing the potential of nature-inspired compounds. Our overarching mission is to develop innovative, rational therapeutic modalities that offer more effective, safer treatment options for patients.
From Discovery to Healing
At SJP Biotec, we are focused on transforming groundbreaking scientific advances into innovative therapeutic solutions. SJP Biotec was founded as a spin-off from the University Medical Centre Mainz under the leadership of Professor Krishnaraj Rajalingam and builds on extensive expertise in oncogenic and immunologic processes, particularly the underlying molecular signaling pathways.
Strategic joint venture
Through a strategic joint venture with KHR Biotec and KRAS Research, we aim to develop next-generation therapeutics in critical areas of oncology, autoimmune diseases, and infectious diseases. Fruitful partnerships with industry, clinical and academic leaders enhance every stage of our drug development efforts — from target discovery and validation through preclinical modeling and early translational research — ensuring that our work is alignment with scientific excellence and rigor.
KRAS Research
Our R&D engine is based in Germany, deeply embedded in the research campus of the University Medical Center Mainz.
KHR Biotec
Our exciting journey started in 2021 with the first flavagline derivatives. KHR Biotec is now occupied with drug repurposing.
